These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

852 related items for PubMed ID: 30375398

  • 1. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H, Fang L, Jiang J, Kuang Y, Wang B, Shang X, Han P, Li Y, Liu M, Zhang Z, Li P.
    Cell Death Dis; 2018 Oct 30; 9(11):1103. PubMed ID: 30375398
    [Abstract] [Full Text] [Related]

  • 2. Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis.
    Wang H, Li Y, Wang Y, Shang X, Yan Z, Li S, Bao W.
    J Gynecol Oncol; 2024 Mar 30; 35(2):e13. PubMed ID: 37921598
    [Abstract] [Full Text] [Related]

  • 3. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
    Wang Y, Wang H, Song T, Zou Y, Jiang J, Fang L, Li P.
    Mol Med Rep; 2015 Aug 30; 12(2):2211-6. PubMed ID: 25824616
    [Abstract] [Full Text] [Related]

  • 4. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
    Fraser M, Bai T, Tsang BK.
    Int J Cancer; 2008 Feb 01; 122(3):534-46. PubMed ID: 17918180
    [Abstract] [Full Text] [Related]

  • 5. Long noncoding RNA PANDAR blocks CDKN1A gene transcription by competitive interaction with p53 protein in gastric cancer.
    Liu J, Ben Q, Lu E, He X, Yang X, Ma J, Zhang W, Wang Z, Liu T, Zhang J, Wang H.
    Cell Death Dis; 2018 Feb 07; 9(2):168. PubMed ID: 29416011
    [Abstract] [Full Text] [Related]

  • 6. Overexpression of Long Noncoding RNA E2F-Mediated Cell Proliferation Enhancing Long Noncoding RNA Is Involved in the Development of Chemoresistance of Cancer Cells to Carboplatin in Ovarian Endometrioid Adenocarcinoma.
    Zhao L, Yang J, Liu X, Fu X, Ding Y, Wang C.
    Cancer Biother Radiopharm; 2019 Nov 07; 34(9):566-571. PubMed ID: 31621389
    [Abstract] [Full Text] [Related]

  • 7. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
    Ge T, Liu T, Guo L, Chen Z, Lou G.
    Exp Cell Res; 2020 Nov 01; 396(1):112241. PubMed ID: 32835657
    [Abstract] [Full Text] [Related]

  • 8. Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving.
    Wang DY, Li N, Cui YL.
    Cancer Res Treat; 2020 Jul 01; 52(3):798-814. PubMed ID: 32124583
    [Abstract] [Full Text] [Related]

  • 9. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
    Zhang X, Qi Z, Yin H, Yang G.
    Theranostics; 2019 Jul 01; 9(4):1096-1114. PubMed ID: 30867818
    [Abstract] [Full Text] [Related]

  • 10. Long non-coding RNA PANDAR promoted radiation and cisplatin-induced DNA damage repair through ATR/CHK1 in NSCLC.
    Zhao S, Yu N, Wang H, Wan Z, Diao C, Chen Y, Liu T, Yang Y, Gao F, Bai C, Cao K, Cai J.
    J Gene Med; 2023 Dec 01; 25(12):e3565. PubMed ID: 37460393
    [Abstract] [Full Text] [Related]

  • 11. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
    Xu S, Fu GB, Tao Z, OuYang J, Kong F, Jiang BH, Wan X, Chen K.
    Oncotarget; 2015 Sep 22; 6(28):26457-71. PubMed ID: 26238185
    [Abstract] [Full Text] [Related]

  • 12. A Novel Long Non-Coding RNA KMU15 Promotes Growth and Chemoresistance of Bladder Cancer.
    Huang Y, Luan T, Bao X, Fu S, Li N, Li H, Wang H, Li C, Wang J.
    Clin Lab; 2019 Dec 01; 65(12):. PubMed ID: 31850704
    [Abstract] [Full Text] [Related]

  • 13. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
    Zhang XY, Zhang M, Cong Q, Zhang MX, Zhang MY, Lu YY, Xu CJ.
    Int J Biochem Cell Biol; 2018 Feb 01; 95():9-16. PubMed ID: 29247711
    [Abstract] [Full Text] [Related]

  • 14. An increase in long non-coding RNA PANDAR is associated with poor prognosis in clear cell renal cell carcinoma.
    Xu Y, Tong Y, Zhu J, Lei Z, Wan L, Zhu X, Ye F, Xie L.
    BMC Cancer; 2017 May 25; 17(1):373. PubMed ID: 28545465
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.
    Yan M, Yang X, Shen R, Wu C, Wang H, Ye Q, Yang P, Zhang L, Chen M, Wan B, Zhang Q, Xia S, Lu X, Shao G, Zhou X, Yu J, Shao Q.
    Cell Death Dis; 2018 Nov 08; 9(11):1123. PubMed ID: 30409964
    [Abstract] [Full Text] [Related]

  • 17. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
    Ji T, Gong D, Han Z, Wei X, Yan Y, Ye F, Ding W, Wang J, Xia X, Li F, Hu W, Lu Y, Wang S, Zhou J, Ma D, Gao Q.
    Cancer Lett; 2013 Dec 01; 341(2):231-9. PubMed ID: 23962558
    [Abstract] [Full Text] [Related]

  • 18. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.
    Bhatt M, Ivan C, Xie X, Siddik ZH.
    Oncotarget; 2017 Feb 14; 8(7):10905-10918. PubMed ID: 28038466
    [Abstract] [Full Text] [Related]

  • 19. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
    Xu J, Wu J, Fu C, Teng F, Liu S, Dai C, Shen R, Jia X.
    J Cell Physiol; 2018 Jun 14; 233(6):5034-5043. PubMed ID: 29219179
    [Abstract] [Full Text] [Related]

  • 20. HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.
    Parmakhtiar B, Burger RA, Kim JH, Fruehauf JP.
    Mol Cancer Res; 2019 Aug 14; 17(8):1675-1686. PubMed ID: 31088908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.